Revolution Medicines (RVMD) Anthony Mancini Sells Shares

What Happened

• Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, sold a total of 1,774 shares on September 16, 2026 in open-market transactions. The filings report 27 shares at a weighted average price of $195.05 (reported value $5,266) and 1,747 shares at $199.30 (reported value $348,183), for total proceeds of roughly $353,449.
• The sale was executed pursuant to a Rule 10b5-1 instruction to satisfy tax withholding obligations upon the vesting of restricted stock units, so this was a tax-withholding sale rather than a discretionary sale for investment purposes.

Key Details

• Transaction dates and prices: 2026-09-16 — 27 shares @ weighted avg $195.05 (executed across prices $195.03–$195.07); 1,747 shares @ $199.30.
• Total reported proceeds: approximately $353,449.
• Holdings after transaction: filing notes holdings include 39,575 restricted stock units.
• Notable footnotes: F1 — sale made under a 10b5-1 plan adopted June 15, 2026 to cover tax withholding; F2 — one sale executed in multiple trades across a small price range; F3 — holdings include 39,575 RSUs.
• Timeliness: Form 4 filed September 18, 2026 for transactions on September 16, 2026 (filed within standard reporting window).

Context

• Because these sales were made under a pre-established 10b5-1 plan to satisfy tax withholding associated with RSU vesting, they are generally viewed as routine and not a clear signal of the insider’s view of the company’s stock. Purchases typically carry more weight for assessing insider conviction.